Common Contracts
2 similar Settlement and Assignment Agreement contracts
Asset purchase and settlement agreement for complement inhibition technology including Soliris (eculizumab)Settlement and Assignment Agreement • September 21st, 2021 • Oklahoma
The Oklahoma Medical Research Foundation and Alexion Pharma has agreed to acquire from OMRF all rights to certain patents related to complement-inhibition technology.
Asset purchase and settlement agreement for complement inhibition technology including Soliris (eculizumab)Settlement and Assignment Agreement • February 18th, 2021 • Oklahoma
The Oklahoma Medical Research Foundation and Alexion Pharma has agreed to acquire from OMRF all rights to certain patents related to complement-inhibition technology.
